Drug Information Related to Letairis
01. GILEAD SCIENCES REPORTS 2ND QTR REVENUES OF $1.28 BILLION. - Free ......
Gilead Sciences, Inc.(Nasdaq: GILD), Foster City, Calif., has
announced its results of operations for the quarter ended June 30, 2008.
Total revenues for the second quarter of 2008 were $1.28 billion, up 22
percent compared to total revenues of $1.05 billion for ...
02. Gilead Announces New Letairis(TM) (ambrisentan) Data for the Treatment...
-- Long-Term Data and Integrated Subgroup Analysis in Patients with
Idiopathic PAH and PAH Associated with Connective Tissue Disease
Presented at the Annual Meeting of the American College of Chest
Physicians --
CHICAGO -- Gilead Sciences, Inc. (Nasdaq: GILD) ...
03. Data from Pivotal Phase III Studies of Gilead's Letairis(R ...
FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today
announced that data from the pivotal Phase III ARIES-1 and ARIES-2
studies of Letairis([R]) were published in Circulation online before
print. Letairis (ambrisentan 5 mg and 10 mg tablets) is indica...
04. Gilead Sciences Announces Second Quarter 2007 Financial Results. - Fre...
- Record Product Sales of $905 Million, Up 53 Percent over Second
Quarter 2006 -
- Total Revenues of $1.0 Billion, Up 53 Percent over Second Quarter
2006 -
- Second Quarter EPS of $0.42 per Share -
- Second Quarter Non-GAAP EPS of $0.46 per Share, Excludi...
05. FDA OKs blood pressure drug - Free Online Library
Patients who suffer from a rare disease that causes continuous high blood pressure in the arteries of the lungs received a new treatment choice Friday.The Food and Drug Administration said it approved Letairis to treat pulmonary arterial hypertension. The condition ca...
06. Gilead Scienes Wins FDA Approval For Treatment For Rare Disease - Free...
Over the past few years Gilead Sciences has built a strong franchise in drugs used to treat HIV.Now, as the biotech company continues to gain traction with its HIV products, it also is branching out onto new turf. Gilead GILD won approval late Friday from the Food and...
07. Data from Pivotal Phase III Studies of Gilead's Letairis® for Pulmona...
FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that data from the pivotal Phase III ARIES-1 and ARIES-2 studies of Letairis([R]) were published in Circulation online before print. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated a...
08. U.S. Food and Drug Administration Approves Gilead's Letairis™ 5 mg a...
Gilead Also Announces Launch of Gilead([TM])Solutions, a Comprehensive Access Program
...
09. FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial ......
M2 PRESSWIRE-18 June 2007-US FDA: FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:18052007 The U.S. Food and Drug Administration (FDA) today approved Letairis (ambrisentan) for the treatmen...